

Table 1. The relationship between ULR and clinical pathology characteristics in HCC.

Characteristics	Entire cohort				Propensity score-matched cohort			
	total	ULR≤5.47	ULR>5.47	P-Value	total	ULR≤5.47	ULR>5.47	P-Value
Age (years)	132	92	40		72	36	36	
≤65	110 (83.3%)	79 (85.9%)	31 (77.5%)		56 (77.8%)	27 (75.0%)	29 (80.6%)	
>65	22 (16.7%)	13 (14.1%)	9 (22.5%)	0.24	16 (22.2%)	9 (25.0%)	7 (19.4%)	0.57
Gender								
Male	111 (84.1%)	76 (82.6%)	35 (87.5%)		61 (84.7%)	30 (83.3%)	31 (86.1%)	
Female	21 (15.9%)	16 (17.4%)	5 (12.5%)	0.61	11 (15.3%)	6 (16.7%)	5 (13.9%)	0.74
BMI (kg/m2)								
≤24	76(57.6%)	51(55.4%)	25 (62.5%)		41 (56.9%)	20 (55.6%)	21 (58.3%)	
>24	56(42.4%)	41(44.6%)	15 (37.5%)	0.45	31 (43.1%)	16 (44.4%)	15 (41.7%)	0.81
HBV infection								
Negative	18 (13.6%)	11 (12.0%)	7 (17.5%)		10 (13.9%)	6 (16.7%)	4 (11.1%)	
Positive	114 (86.4%)	81 (88.0%)	33 (82.5%)	0.39	62 (86.1%)	30 (83.3%)	32 (88.9%)	0.50
Tumor size (cm)#								
≤5	76 (58.5%)	62 (67.4%)	14 (35.0%)		28 (38.9%)	14 (38.9%)	14 (38.9%)	
>5	56 (41.5%)	30 (32.6%)	26 (65.0%)	<0.01*	44 (61.1%)	22 (61.1%)	22 (61.1%)	1.00
Serum AFP (ng/ml)								
≤400	89 (67.4%)	63 (68.5%)	26 (65.0%)		48 (66.7%)	25 (69.4%)	23 (63.9%)	
>400	43 (32.6%)	29 (31.5%)	14 (35.0%)	0.70	24 (33.3%)	11 (30.6%)	13 (36.1%)	0.62
Serum Uric Acid (mmol/L)								
Normal	105 (79.5%)	77 (83.7%)	28 (70.0%)		57 (79.2%)	31 (86.1%)	26 (72.2%)	
Abnormal	27 (20.5%)	15 (16.3%)	12 (30.0%)	0.07	15 (20.8%)	5 (13.9%)	10 (27.8%)	0.15
Lymphocyte count (10⁹/L)								
Normal	80 (60.6%)	73 (79.3%)	7 (17.5%)		38 (52.8%)	32 (88.9%)	6 (16.7%)	
Abnormal	52 (39.4%)	19 (20.7%)	33 (82.5%)	<0.001*	34 (47.2%)	4 (11.1%)	30 (83.3%)	<0.001*
Serum albumin (g/L)								
≤40	73 (55.3%)	53 (57.6%)	20 (50.0%)		39 (54.2%)	20 (55.6%)	19 (52.8%)	
>40	59 (44.7%)	39 (42.6%)	20 (50.0%)	0.42	33 (45.8%)	16 (44.4%)	17 (47.2%)	0.81
Cirrhosis								
Absent	50 (37.9%)	32 (34.8%)	18 (45.0%)		27 (37.5%)	13 (36.1%)	14 (38.9%)	
Present	82 (62.1%)	60 (65.2%)	22 (55.0%)	0.27	45 (62.5%)	23 (63.9%)	22 (61.1%)	0.81
Cardiovascular disease								
Absent	114 (86.4%)	80 (87.0%)	34 (85.0%)		67 (93.1%)	34 (94.4%)	33 (91.7%)	
Present	18 (13.6%)	12 (13.0%)	6 (15.0%)	0.76	5 (6.9%)	2 (5.6%)	3 (8.3%)	1.00
T2DM								
Absent	121 (91.7%)	82 (89.1%)	39 (97.5%)		69 (95.8%)	34 (94.4%)	35 (97.2%)	
Present	11 (8.3%)	10 (10.9%)	1 (2.5%)	0.17	3 (4.2%)	2 (5.6%)	1 (2.8%)	1.00

Note: ULR: uric acid to lymphocyte ratio. #Tumor size was measured by the length of the largest tumor nodule.